These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 9819100)

  • 1. Triglyceride as a risk factor for coronary artery disease.
    Gotto AM
    Am J Cardiol; 1998 Nov; 82(9A):22Q-25Q. PubMed ID: 9819100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease.
    Ginsberg HN
    Curr Cardiol Rep; 1999 Sep; 1(3):233-7. PubMed ID: 10980847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.
    Grundy SM
    Am J Cardiol; 1998 Feb; 81(4A):18B-25B. PubMed ID: 9526809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The triglyceride connection in atherosclerosis.
    Geurian K; Pinson JB; Weart CW
    Ann Pharmacother; 1992 Sep; 26(9):1109-17. PubMed ID: 1421678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment.
    Ferguson EE
    Dis Mon; 2000 Jul; 46(7):421-503. PubMed ID: 10943222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL and triglyceride as therapeutic targets.
    Fruchart JC; Duriez P
    Curr Opin Lipidol; 2002 Dec; 13(6):605-16. PubMed ID: 12441884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    Das Pradhan A; Glynn RJ; Fruchart JC; MacFadyen JG; Zaharris ES; Everett BM; Campbell SE; Oshima R; Amarenco P; Blom DJ; Brinton EA; Eckel RH; Elam MB; Felicio JS; Ginsberg HN; Goudev A; Ishibashi S; Joseph J; Kodama T; Koenig W; Leiter LA; Lorenzatti AJ; Mankovsky B; Marx N; Nordestgaard BG; Páll D; Ray KK; Santos RD; Soran H; Susekov A; Tendera M; Yokote K; Paynter NP; Buring JE; Libby P; Ridker PM;
    N Engl J Med; 2022 Nov; 387(21):1923-1934. PubMed ID: 36342113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
    Toth PP; Zarotsky V; Sullivan JM; Laitinen D
    Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
    Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
    Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal metabolism of postprandial lipoproteins in patients with non-insulin-dependent diabetes mellitus is not related to coronary artery disease.
    Syvänne M; Hilden H; Taskinen MR
    J Lipid Res; 1994 Jan; 35(1):15-26. PubMed ID: 8138716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?
    Taskinen MR
    Diabetes Res Clin Pract; 2003 Jul; 61 Suppl 1():S19-26. PubMed ID: 12880691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.